Sotera Health Company SHC
Set alert
16.42 USD -1.32 -7.47%
As of Nov 3, 12:58 PM ET
16.41 Day range 17.28
13.09 52-week range 19.85
- YTD
- -6.94%
- 1 year
- -1.17%
- Open
- 17.09
- Prev close
- 17.74
- Mkt cap
- 4.68B
- Vol
- 1.98M
- Avg vol
- 2.30M
- EPS
- 0.57
- P/E
- 28.78
- Div yield
- 0.00%
More statistics
- Low
- 16.41
- High
- 17.28
- Forward P/E
- 16.50
- Beta
- 1.93
- Short ratio
- 7.82
- Inst. own
- 101.28%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 3, 2026
- 50-d avg
- 18.52
- 200-d avg
- 17.00
- 1y target
- 22.61
1Y chart
Events in this range
- Nov 4, 2025Earnings: 0.26; estimate 0.22; surprise 18.18%
- Feb 24, 2026Earnings: 0.26; estimate 0.24; surprise 8.33%
- May 5, 2026Earnings: 0.18; estimate 0.17; surprise 5.88%
- Jun 24, 2026Rating: Barclays · Overweight → Overweight
- Aug 6, 2026Earnings: 0.26; estimate 0.2389; surprise 8.83%
- Aug 7, 2026Rating: JP Morgan · Neutral → Neutral
- Aug 7, 2026Rating: Piper Sandler · Overweight → Overweight
- Aug 7, 2026Rating: Barclays · Overweight → Overweight
- Aug 7, 2026Rating: Citigroup · Buy → Buy
- Oct 14, 2026Downgrade: JP Morgan · Neutral → Underweight
- Nov 3, 2026Earnings: —; estimate 0.2687; surprise —%
Signals (49)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Nov 3, 2026 | 3 hours ago |
| MACD: Sell Signal | Nov 3, 2026 | 3 hours ago |
| RSI: Oversold | Nov 3, 2026 | 3 hours ago |
| SMA: Bearish | Oct 30, 2026 | 4 days ago |
| SMA: Bullish | Oct 28, 2026 | 6 days ago |
| MACD: Buy Signal | Oct 22, 2026 | 1 week ago |
| SMA: Bearish | Sep 30, 2026 | 1 month ago |
| SMA: Bullish | Sep 29, 2026 | 1 month ago |
| SMA: Bearish | Sep 23, 2026 | 1 month ago |
| SMA: Bullish | Sep 14, 2026 | 1 month ago |
| SMA: Bearish | Sep 9, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 28, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 20, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 18, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 6, 2026 | 2 months ago |
| MACD: Sell Signal | Jul 17, 2026 | 3 months ago |
| RSI: Overbought | Jul 10, 2026 | 3 months ago |
| RSI: Overbought | Jun 30, 2026 | 4 months ago |
| SMA: Bullish | Jun 24, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 24, 2026 | 4 months ago |
Newest 20 of 49.
Key statistics
- Market cap
- 5.06B
- Enterprise value
- 7.09B
- Trailing P/E
- 31.12
- Forward P/E
- 16.50
- PEG ratio
- 1.31
- Price / sales
- 4.16
- Price / book
- 7.60
- EPS (TTM)
- 0.57
- Beta
- 1.93
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 13.44%
- Revenue (TTM)
- 1.22B
- Revenue growth
- 9.20%
- Free cash flow
- 153.97M
- Total cash
- 356.95M
- Total debt
- 2.27B
- Return on equity
- 27.78%
- Shares outstanding
- 285.37M
- Short % of float
- 6.51%
- 50-day average
- 18.52
- 200-day average
- 17.00
Analyst view
Consensus: buy
Buy
Price target (mean) 22.61 +37.7% upside
Now 16.42
- Target (low)
- 17.00
- Target (mean)
- 22.61
- Target (high)
- 25.00
Ratings (0m) 10 8 buy · 1 hold · 1 sell
- Strong buy3
- Buy5
- Hold1
- Sell0
- Strong sell1
Next earnings
Nov 3, 2026
Expected Nov 3, 2026. Consensus EPS estimate 0.26864.
Financials — quick view
SHC Revenue — quarterly 321.38M
SHC Net income — quarterly 53.64M
SHC EPS — quarterly 0.19
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 3, 2026 | Sep 30, 2026 | 0.2687 | — | — | — |
| Aug 6, 2026 | Jun 30, 2026 | 0.2389 | 0.26 | +0.02 | +8.83% |
| May 5, 2026 | Mar 31, 2026 | 0.17 | 0.18 | +0.01 | +5.88% |
| Feb 24, 2026 | Dec 31, 2025 | 0.24 | 0.26 | +0.02 | +8.33% |
| Nov 4, 2025 | Sep 30, 2025 | 0.22 | 0.26 | +0.04 | +18.18% |
| Aug 8, 2025 | Jun 30, 2025 | 0.17 | 0.20 | +0.03 | +17.65% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 14, 2026 | JP Morgan | down | Neutral | Underweight |
| Aug 7, 2026 | Citigroup | main | Buy | Buy |
| Aug 7, 2026 | Barclays | main | Overweight | Overweight |
| Aug 7, 2026 | Piper Sandler | reit | Overweight | Overweight |
| Aug 7, 2026 | JP Morgan | main | Neutral | Neutral |
| Jun 24, 2026 | Barclays | main | Overweight | Overweight |
About Sotera Health Company
Sotera Health Company provides sterilization solutions, lab testing, and advisory services for the healthcare industry in the United States, Canada, Europe, and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. The Sterigenics segment offers outsourced terminal sterilization and irradiation services using gamma irradiation, ethylene oxide processing, and electron beam irradiation technologies for medical devices, pharmaceutical, and food safety and advanced applications markets. The Nordion segment provides Cobalt-60 used in the sterilization and irradiation processes for the medical device, pharmaceutical, food safety, and high-performance materials industries, as well as in the treatment of cancer. It also offers gamma irradiation systems. The Nelson Labs segment provides outsourced microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries. The company was formerly known as Sotera Health Topco, Inc. and changed its name to Sotera Health Company in October 2020. Sotera Health Company was incorporated in 2015 and is headquartered in Broadview Heights, Ohio.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- United States
- Website
- soterahealth.com
News
- Here's What Key Metrics Tell Us About Sotera Health (SHC) Q3 Earnings
- Sotera Health Q3 2026 Earnings Call Transcript
- Sotera Health Company (SHC) Beats Q3 Earnings and Revenue Estimates
- Sotera Health Q3 Adj. EPS $0.29 Beats $0.27 Estimate, Sales $324.886M Beat $319.774M Estimate
- Sotera Health Affirms FY2026 Adj EPS Guidance of $0.95-$1.01 vs $0.98 Est; Lowers FY2026 Sales Guidance from $1.236B-$1.254B to $1.233B-$1.250B vs $1.247B Est
- Sotera Health Reports Solid Third-Quarter and Year-to-Date 2026 Results
- Sotera Health Announces Third-Quarter 2026 Earnings Release Date
- JP Morgan Downgrades Sotera Health to Underweight, Announces $17 Price Target
- Transcript: Sotera Health Q2 2026 Earnings Conference Call
- Squarepoint Ops LLC Sells 102,776 Shares of Sotera Health Company $SHC
Your note
Sign in to keep a note on SHC — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CUNNINGHAM SEAN LAURENCE | Director | Stock Award(Grant) | May 21, 2026 | 95,751 |
| DIMITRIEF ALEXANDER | General Counsel | Conversion of Exercise of derivative security | Mar 1, 2026 | 319,981 |
| KLEE ANN R | Director | Stock Award(Grant) | May 21, 2026 | 140,926 |
| LYONS JONATHAN M | Chief Financial Officer | Stock Award(Grant) | Mar 1, 2026 | 228,620 |
| NEARY JAMES C | Director | Stock Award(Grant) | May 21, 2026 | 95,751 |
| PETRAS MICHAEL B. JR. | Officer and Director | Sale | Aug 16, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Sessa Capital IM, L.P. | 9.48% | 27,050,000 | 479.87M | Jun 29, 2026 |
| Darsana Capital Partners, LP | 9.46% | 27,000,000 | 478.98M | Jun 29, 2026 |
| Blackrock Inc. | 8.46% | 24,148,424 | 428.39M | Jun 29, 2026 |
| Sculptor Capital LP | 8.41% | 24,000,000 | 425.76M | Jun 29, 2026 |
| Sachem Head Capital Management, LP | 5.45% | 15,560,000 | 276.03M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.26% | 12,170,699 | 215.91M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Mid-Cap ETF | 3.56% | 10,168,349 | 180.39M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.02% | 8,614,655 | 152.82M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.18% | 6,215,762 | 110.27M | Jun 29, 2026 |
| JANUS INVESTMENT FUND-Janus Henderson Contrarian Fund | 2.05% | 5,853,280 | 103.84M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 1.25% | 3,578,222 | 63.48M | Jun 29, 2026 |
| T. Rowe Price Small-Cap Stock Fund, Inc. | 1.09% | 3,120,870 | 55.36M | Jun 29, 2026 |